Follow
Eduard Teixidor Vilà (ORCID: 0000-0001-6795-3218)
Eduard Teixidor Vilà (ORCID: 0000-0001-6795-3218)
Other namesORCID: 0000-0001-6795-3218
Catalan Institute of Oncology (ICO).
Verified email at iconcologia.net
Title
Cited by
Cited by
Year
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
C Monteiro, L Miarka, M Perea-García, N Priego, P Garcia-Gomez, ...
Nature Medicine 28 (4), 752-765, 2022
372022
Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma
E Teixidor, E Sais, CA Vásquez, W Carbajal, A Hernández, G Sánchez, ...
Oncotarget 9 (68), 33043, 2018
112018
The dark side of immunotherapy: challenges facing the new hope in cancer treatment
E Teixidor, J Bosch-Barrera
Annals of Translational Medicine, 2019
72019
Silibinin overcomes EMT-Driven lung cancer resistance to New-Generation ALK inhibitors
S Verdura, JA Encinar, E Teixidor, A Segura-Carretero, V Micol, E Cuyàs, ...
Cancers 14 (24), 6101, 2022
42022
Clinical management of COVID-19 in cancer patients with the STAT3 inhibitor silibinin
J Bosch-Barrera, A Roqué, E Teixidor, MC Carmona-Garcia, A Arbusà, ...
Pharmaceuticals 15 (1), 19, 2021
22021
Silibinin is a suppressor of the metastasis-promoting transcription factor ID3
S Verdura, JA Encinar, A Gratchev, À Llop-Hernández, J López, ...
Phytomedicine, 155493, 2024
2024
EP02. 01-05 Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases
J Bosch-Barrera, E Teixidor, A Sanvisens, M Puigdemont, J Trallero, ...
Journal of Thoracic Oncology 18 (11), S426-S427, 2023
2023
Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung …
E Teixidor, E Sais, CA Vásquez, W Carbajal, A Hernández, G Sánchez, ...
Oncotarget 14, 668, 2023
2023
P2. 01-49 Targeting STAT3-Positive Reactive Astrocytes with Silibinin in the Therapeutic Landscape of Non-Small-Cell Lung Cancer with Brain Metastases
J Bosch-Barrera, N Priego, M Puigdemont, E Sais, N Quer, A Izquierdo, ...
Journal of Thoracic Oncology 14 (10), S658, 2019
2019
P1. 03-035 Efficacy of Nintedanib and Docetaxel in Combination with the Nutraceutical Use of Silibinin in Advanced NSCLC
JB Barrera, E Sais, S Verdura, E Cuyas, D Roa, A Hernández, A Izquierdo, ...
Journal of Thoracic Oncology 12 (11), S1964, 2017
2017
The system can't perform the operation now. Try again later.
Articles 1–10